Skip to main content
SpringerLink
Log in

Telmisartan

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Telmisartan is a nonpeptide angiotensin II receptor antagonist which selectively and insurmountably inhibits the angiotensin II AT1 receptor subtype without affecting other receptor systems involved in cardiovascular regulation.

  • ▴ Oral telmisartan dose-dependently reduced blood pressure (BP) in various animal models of hypertension. In transgenic rats, telmisartan reduced cardiac hypertrophy and glomerulosclerosis.

  • ▴ When administered at dosages of 40 to 160mg once daily to patients with mild to moderate hypertension, telmisartan significantly reduced systolic and diastolic BP compared with placebo and was at least as effective as atenolol 50 or 100mg and lisinopril 10 to 40mg. One study showed telmisartan 80 mg/day to be more effective than enalapril 20 mg/day.

  • ▴ In 2 studies that used ambulatory BP monitoring, once daily telmisartan provided better control of diastolic BP for the full dosing interval than losartan potassium 50mg or amlodipine 5 or 10mg.

  • ▴ In a single study in patients with severe hypertension, a telmisartan-based regimen had antihypertensive efficacy similar to that of an enalapril-based regimen.

  • ▴ Telmisartan had a tolerability profile similar to that of placebo in clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wienen W, Hauel N, Van MJCA, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993 Sep; 110: 245–52

    Article  PubMed  CAS  Google Scholar 

  2. van Meel JCA, Hauel N, Entzeroth M, et al. Antihypertensive effects of the angiotensin receptor antagonist, BIBR 277, in conscious renal hypertensive and spontaneously hypertensive rats [abstract]. Br J Pharmacol 1993 Apr; 108 Suppl.: 191P

  3. Wienen W, Entzeroth M, Diederen W, et al. Pharmacology and antihypertensive effects of telmisartan, an AT1-selective angiotensin II receptor antagonist [poster]. 1st International Symposium on Angiotensin II Antagonism; 1997 Sep 28–Oct 1; London

  4. Winquist R, Panzenbeck M, Madwed J, et al. The effects of BIBR277, an angiotensin II type I (ATI) receptor antagonist in conscious monkeys [abstract]. FASEB J 1994 Mar 18; 8 (Pt 2): A882

    Google Scholar 

  5. van Meel JCA, Redemann N, Haigh RM. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. Arzneimittel Forschung 1996 Aug; 46: 755–9

    PubMed  Google Scholar 

  6. Schierok H, Pairet M, Hauel N, et al. Effects of telmisartan, a new angiotensin AT1 receptor antagonist, on renal excretory function in conscious dogs [abstract]. 1st International Symposium on Angiotensin II Antagonism; 1997 Sep 28–Oct 1; London

  7. Böhm M, Lippoldt A, Wienen W, et al. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996 Oct-Nov; 163/164: 217–21

    Article  Google Scholar 

  8. Böhm M, Lee MA, Kreutz R, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995 Aug; 13: 891–9

    Article  PubMed  Google Scholar 

  9. van Heiningen PNM, van Lier JJ, de Bruin H, et al. Single dose study on the pharmacodynamics and pharmacokinetics of the angiotensin II antagonist BIBR0227SE [abstract]. Pharm World Sci 1994 Jun 10; 16 Suppl. D: D4

    Google Scholar 

  10. Slangier J, Schmid J, Tiirck D, et al. Pharmacokinetics of [14C]-radiolabelled telmisartan, a potent angiotensin II antagonist, in healthy male subjects [poster]. 1st International Symposium on Angiotensin II Antagonism; 1997 Sep 28–Oct 1; London

  11. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998 Jul–Aug; 15: 206–17

    CAS  Google Scholar 

  12. Busch U, Heinzel G, Roth W Animal pharmacokinetics of telmisartan and their application to man [poster]. 1st International Symposium on Angiotensin II Antagonism; 1997 Sep 28–Oct 1; London

  13. Schmid J, Beschke K, Ebner T, et al. In-vivo and in-vitm biotransformation of telmisartan [poster]. 1st International Symposium on Angiotensin II Antagonism: 1997 Sep 28–Oct 1: London

  14. Su CAPF, van Lier JJ, Schwietert HR, et al. Influence of telmisartan, a non-peptide angiotensin II receptor antagonist, on steady state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1996; 353 Suppl.: R–155

    Google Scholar 

  15. Elliott HL. The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension [abstract no. E116]. Am J Hypertens 1998; 11 (4 Pt 2): 124A

    Article  Google Scholar 

  16. Schelling A, Ramsay LE, Freytag F. The long term safety and efficacy of telmisartan compared to atenolol in the treatment of hypertension [poster]. 17th Scientific Meeting of the International Society of Hypertension; 1998 Jun 7–11; Amsterdam

  17. Neutel J, Frishman W, Oparil S, et al. A comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension [poster]. American Society of Hypertension 13th Scientific Meeting; 1998 May 13–16; New York

  18. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998 Jul/Aug; 15: 229–40

    CAS  Google Scholar 

  19. Neutel JM. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension [poster]. American Society of Hypertension 13th Scientific Meeting; 1998 May 13–16; New York (NY)

  20. Mallion JM, Lacourciére Y, Telmisartan Blood Pressure Monitoring Group. A comparison of the blood pressure profile of telmisartan and losartan at 18-24 hours post-dosing as measured by ambulatory blood pressure monitoring [abstract no. E141]. Am J Hypertens 1998; 11 (4 Pt 2): 262A

    Article  Google Scholar 

  21. Lacourciére Y, Neutel JM, Smith DHG. Twenty-four hour blood pressure monitoring to compare the efficacy and duration of action of the ATII antagonist telmisartan to amlodipine [abstract]. Am J Hypertens 1997 Apr; 10 (Pt 2): 7A

    Article  Google Scholar 

  22. Lacourciére Y. A comparison of cough in hypertensive patients receiving telmisartan, lisinopril or placebo [abstract no. E093]. Am J Hypertens 1998; 11 (4 Pt 2): 119A

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Karen J. McClellan & Anthony Markham

Authors
  1. Karen J. McClellan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen J. McClellan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McClellan, K.J., Markham, A. Telmisartan. Drugs 56, 1039–1044 (1998). https://doi.org/10.2165/00003495-199856060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856060-00007

Keywords

Search

Navigation